Advisors Asset Management Inc. cut its stake in Novo Nordisk A/S (NYSE:NVO) by 34.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,181 shares of the company’s stock after selling 3,844 shares during the period. Advisors Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $346,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of NVO. Geode Capital Management LLC grew its stake in shares of Novo Nordisk A/S by 20.6% in the first quarter. Geode Capital Management LLC now owns 28,778 shares of the company’s stock worth $985,000 after purchasing an additional 4,910 shares in the last quarter. Bessemer Group Inc. grew its stake in shares of Novo Nordisk A/S by 0.7% in the second quarter. Bessemer Group Inc. now owns 33,388 shares of the company’s stock worth $1,431,000 after purchasing an additional 247 shares in the last quarter. Sei Investments Co. grew its stake in shares of Novo Nordisk A/S by 79.2% in the second quarter. Sei Investments Co. now owns 17,151 shares of the company’s stock worth $736,000 after purchasing an additional 7,578 shares in the last quarter. TD Asset Management Inc. grew its stake in shares of Novo Nordisk A/S by 49.2% in the second quarter. TD Asset Management Inc. now owns 64,170 shares of the company’s stock worth $2,752,000 after purchasing an additional 21,157 shares in the last quarter. Finally, Global X Management Co. LLC grew its stake in shares of Novo Nordisk A/S by 2.9% in the second quarter. Global X Management Co. LLC now owns 106,331 shares of the company’s stock worth $4,561,000 after purchasing an additional 3,034 shares in the last quarter. 6.18% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider Eric S. Sprott bought 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 8th. The stock was acquired at an average price of $8.34 per share, with a total value of $417,000.00. Company insiders own 0.07% of the company’s stock.

Several research analysts have recently issued reports on the company. Zacks Investment Research cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Monday, September 18th. Bank of America raised Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a research note on Wednesday. BNP Paribas cut Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a research note on Monday, September 25th. BidaskClub raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research note on Saturday, August 12th. Finally, Morgan Stanley raised Novo Nordisk A/S from an “equal weight” rating to an “overweight” rating in a research note on Friday, December 1st. Three analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $55.00.

Shares of Novo Nordisk A/S (NYSE:NVO) traded down $0.29 during mid-day trading on Thursday, reaching $51.78. The company had a trading volume of 606,717 shares, compared to its average volume of 2,098,421. Novo Nordisk A/S has a fifty-two week low of $32.83 and a fifty-two week high of $52.45. The company has a market capitalization of $129,285.00, a PE ratio of 22.14, a P/E/G ratio of 3.01 and a beta of 0.63.

TRADEMARK VIOLATION NOTICE: This report was first posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this report on another site, it was stolen and republished in violation of US & international trademark & copyright law. The original version of this report can be accessed at https://theolympiareport.com/2017/12/07/advisors-asset-management-inc-has-346000-holdings-in-novo-nordisk-as-nvo.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with Analyst Ratings Network's FREE daily email newsletter.